The Baupost Group LLC recently announced the acquisition of new stake in Atara Biotherapeutics Inc. (NASDAQ:ATRA). The institutional investor has increased its shareholding in the Healthcare company by 12.31% to 9.12 million shares with purchase of 1.0 million shares. This fresh investment now brings its stake to 9.51% valued currently at $24.72 million. In addition, BlackRock Fund Advisors raised its holdings by 0.13 million to 7.31 million shares. And The Vanguard Group, Inc. has lifted its position by 9.36% or 0.6 million shares – to 7.06 million shares.
With over 1.37 million Atara Biotherapeutics Inc. (ATRA) shares trading Tuesday and a closing price of $2.08 on the day, the dollar volume was approximately $2.86 million. The shares have shown a negative half year performance of -51.29% and its price on 05/23/23 lost nearly -0.95%. Currently, there are 103.97M common shares owned by the public and among those 94.28M shares have been available to trade.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 8 analysts who have offered their price forecasts for ATRA have a consensus price objective of $14.32. The analysts have set the share’s price value over the next 12 months at a high of $31.00 and a low of $2.00. The average price target is 87.1% above its recent price level and a downside to the estimated low will see the stock lose -4.0% over that period. But an upside of 93.29% will see the stock hit the forecast high price target while median target price for the stock is $12.45.
Insiders at the company have transacted a total of 30 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 12 of these insider trades were purchases, accounting for 925,114 shares. Insider sales of the common stock occurred on 18 occasions, with total insider shares sold totaling 112,503 shares.
The top 3 mutual fund holders in Atara Biotherapeutics Inc. are SPDR S&P Biotech ETF, Vanguard Total Stock Market ETF, and JPMorgan Small Cap Growth Fund. SPDR S&P Biotech ETF owns 4.86 million shares of the company’s stock, all valued at over $13.18 million. The company bought an additional 85140.0 shares recently to bring their total holdings to about 5.07% of the shares outstanding. JPMorgan Small Cap Growth Fund bought 51102.0 shares to bring its total holdings to over 2.48 million shares at a value of $6.72 million. JPMorgan Small Cap Growth Fund now owns shares totaling to 2.58% of the shares outstanding.
Shares of Atara Biotherapeutics Inc. (NASDAQ: ATRA) opened at $2.08, down -$0.02 from a prior closing price of $2.10. However, the script later moved the day high at 2.2850, down -0.95%. The company’s stock has a 5-day price change of 0.00% and -50.83% over the past three months. ATRA shares are trading -36.59% year to date (YTD), with the 12-month market performance down to -59.69% lower. It has a 12-month low price of $1.94 and touched a high of $9.34 over the same period. ATRA has an average intraday trading volume of 1.44 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -15.96%, -23.70%, and -45.67% respectively.
Institutional ownership of Atara Biotherapeutics Inc. (NASDAQ: ATRA) shares accounts for 103.98% of the company’s 103.97M shares outstanding. Mutual fund holders own 45.22%, while other institutional holders and individual stakeholders account for 60.24% and 12.28% respectively.
It has a market capitalization of $197.06M and a beta (3y monthly) value of 0.96. The earnings-per-share (ttm) stands at -$2.08. Price movements for the stock have been influenced by the stock’s volatility, which stands at 7.70% over the week and 10.05% over the month.
Analysts forecast that Atara Biotherapeutics Inc. (ATRA) will achieve an EPS of -$0.65 for the current quarter, -$0.65 for the next quarter and -$1.87 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.76 while analysts give the company a high EPS estimate of -$0.56. Comparatively, EPS for the current quarter was $0.18 a year ago. Earnings per share for the fiscal year are expected to increase by 38.40%, and 26.40% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 8 brokerage firm advisors rate Atara Biotherapeutics Inc. (ATRA) as a “Moderate Buy” at a consensus score of 2.70. Specifically, 4 Wall Street analysts polled rate the stock as a buy, while 2 of the 8 advise that investors “hold,” and 2 rated it as a “Sell.”
Leave a Reply